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Radiation Oncology Biol Phys. 2005;5:1427-31.The role of methylene blue in serotonin syndrome following cardiac
transplantation: A case report and review of the literatureKendra J. Grubb,MD,a Jamie L.W. Kennedy,MD,b James D. Bergin,MD,b Danja S.Groves,MD, PhD,c and
John A. Kern, MD,a Charlottesville, VaVasoplegic syndrome (VS) is a common complication of
cardiopulmonary bypass, with an incidence reported be-
tween 5% and 25% for all cardiac operations.1,2
Associated with increased morbidity and mortality,2,3 VS
is characterized by severe systemic arterial hypotension
(mean arterial pressure,<50 mm Hg) and low systemic
vascular resistance (<800 dyne/s/cm5).1,3 The syndrome
is particularly troubling in orthotopic heart transplant
recipients as a result of the untoward effects of increased
fluid and vasopressor requirements for resuscitation.
Furthermore, VS is reported to occur in as many as 45%
of patients with a ventricular assist device at the time of
transplantation, making this a particularly high-risk surgical
population.4
The blunting of nitric oxide release has been hypothe-
sized to counter the endothelial dysfunction thought to
cause vasoplegia. Methylene blue interacts with nitric
oxide-mediated pathways via a number of mechanisms, in-
cluding direct nitric oxide binding, inhibition of soluble
guanylate cyclase, and inhibition of nitric oxide syn-
thase.5-7 Methylene blue has been shown to reverse
refractory hypotension associated with vasoplegia.8-10
Furthermore, the benefits of methylene blue for thetreatment of VS have been well documented in cardiac
surgery, and its usage associated with reduced mortality
and morbidity.11,12
In an effort to circumvent the morbidity and mortality as-
sociated with VS, we have implemented successfully an in-
traoperative protocol that includes administration of
methylene blue for VS resistant to vasopressor treatment.
Until now, scant information has been reported about the
untoward effects of methylene blue in the cardiac transplant
patient population. Herein, we describe the first case of
methylene blue-induced serotonin toxicity in a patient after
cardiac transplant. A review of the current literature and
U.S. Federal Drug Administration (FDA) warnings are
included.
CASE REPORT
A 60-year-old male with history of nonischemic cardio-
myopathy and end-stage heart failure underwent placement
of a left ventricular assist device (LVAD) along with re-
placement of a mechanical aortic valve with a porcine pros-
thesis inMarch 2011. His LVAD course was complicated by
multiple driveline infections with Pseudomonas, Serratia,
and, most recently, Achromobacter. He was therefore listed
for heart transplantation as a United Network for Organ
Sharing status 1A. A donor organ became available and
he was brought to the hospital for preoperative management
of anticoagulation and preparation for transplant. Comor-
bidities included insulin-dependent diabetes mellitus, hy-
pertension, obesity status-post gastric bypass surgery,
peptic ulcer disease, chronic kidney disease, gout, and de-
pression, for which he was taking escitalopram 20 mg per
ora daily as well as trazodone 100 mg daily at bedtime.
He underwent a third-time redo sternotomy with femoral
cannulation and initiation of cardiopulmonary bypass. After
the aortic crossclamp was placed, he was noted to havediovascular Surgery c Volume 144, Number 5 e113
FIGURE 2. The Hunter serotonin toxicity criteria.16
1. Recent addition or increase in a known serotonergic agent 
2. Absence of other possible etiologies (infection, substance abuse, withdrawl, etc.) 
3. No recent addition or increase of a neuroleptic agent 
4. At least three of the following symptoms:  
a. Mental status changes (confusion, hypomania) 
b. Agitation 
c. Myoclonus 
d. Hyperreflexia 
e. Diaphoresis 
f. Shivering 
g. Tremor 
h. Diarrhea 
i. Incordination 
j. Fever 
FIGURE 1. Sternbach’s criteria.15
Case Reportsepisodes of hypotension during the extensive lysis of adhe-
sions for LVAD removal. Intermittent boluses of phenyle-
pherine were administered to maintain a sufficient mean
arterial pressure. Subsequently, a methylene blue 1-mg/kg
bolus followed by continuous infusion of 0.5 mg/kg per
hour was administered. The hypotension resolved and a tar-
get mean arterial pressure>50 mm Hg on cardiopulmonary
bypass was maintained. The remainder of the heart trans-
plantation was unremarkable, with early recovery of normal
ventricular function.
Postoperatively, the patient was noted to have delayed re-
covery from anesthesia. His physical examination was re-
markable for ocular clonus, mydriasas, lateral nystagmus,
and subsequent myoclonic jerks and shivering, as well as
hypertonicity. He then developed a temperature of 40C
with concomitant hypoxia. His pressure requirement was
moderate, with normal cardiac output by thermal dilution,
but he exhibited a low mixed venous saturation consistent
with a hypermetabolic state. Laboratory tests revealed
a peak white cell count of 18.39 3 109 k/mL, an elevated
creatinine level that peaked at 3.3 mmol/L from a preopera-
tive baseline of 1.7 mmol/L, and an increasing potassium
level with a peak at 5.1 mmol/L. Creatine phosphokinase
peaked at 1406 U/L. Computed tomography of the head re-
vealed no acute pathology. Electroencephalography dem-
onstrated slowing of electrocerebral function, consistent
with encephalopathy resulting from toxic, metabolic, or
pharmacologic changes. He was managed expectantly,
and a neurology consult and toxicology consult were
initiated.
A literature review was then undertaken querying for
‘‘methylene blue’’ and ‘‘nystagmus.’’ Multiple reports and
reviews were found describing the role of methylene blue
in serotonin syndrome and serotonin toxicity in particular
patients taking antidepressants.13,14 Based on his
preoperative medication profile, clinical findings, negative
head computed tomographic scan, and laboratory results,
the diagnosis of serotonin syndrome was made. In that
there is no treatment for serotonin syndrome, the patient
was sedated with midazolam for 24 hours to allow
clearance of methylene blue, and he remained intubated.
The midazolam was weaned and no neurologic
manifestations were noted 48 hours postoperatively. The
patient was then extubated and recovered unremarkably.
He was discharged to home on postoperative day 17.
DISCUSSION
Serotonin Syndrome
Serotonin syndrome is well described in the psychiatric
and psychopharmacologic literature. The syndrome mani-
fests at toxic levels of serotonergic agonism of central ner-
vous system and peripheral serotonergic receptors.15-17
Most often this occurs in the setting of intentional
overdose of antidepressants or from therapeutice114 The Journal of Thoracic and Cardiovascular Surcombination drug usage. The excess serotonin produces
a spectrum of clinical findings, in a concentration-
dependent toxicity, ranging from subtle mental status
changes to a life-threatening adverse drug reaction. A triad
of clinic features including (1) autonomic signs, (2) neuro-
muscular changes, and (3) altered mental status are salient
features in the diagnosis of serotonin syndrome.16
In 1991, Sternbach15 derived diagnostic criteria for se-
rotonin syndrome based on a review of case reports and
case series. The criteria diagnose serotonin syndrome as
the presence of 3 specific clinical features in the set-
ting of known usage of a serotonergic medication
(Figure 1).
Because of the ambiguity of Sternbach’s model, Dunkley
and colleagues16 revised the criteria to diagnose serotonin
toxicity accurately, based on review of 2222 patients pre-
senting with overdose of serotonergic agents to the Hunter
Area Toxicology Service in Australia from January 1987
to November 2002. The redefined criteria simplified the di-
agnosis for serotonin toxicity as well as increased the sensi-
tivity (84%) and specificity (97%) of the model. To predict
serotonin toxicity accurately, only the following clinical
findings are needed: clonus (spontaneous, inducible, or oc-
ular), agitation, diaphoresis, tremor, and/or hyperreflexia
(Figure 2). Clonus is the most important clinical feature,gery c November 2012
TABLE 1. Drugs implicated in serotonin syndrome associatedwith the
administration ofmethylene blue in the Food andDrugAdministration
Adverse Event Reporting System
Class Generic name Brand names
Selective serotonin reuptake
inhibitors
Paroxetine Paxil, Paxil CR
Fluvoxamine Luvox, Luvox CR
Fluoxetine Prozac, Symbyax
Sertraline Zoloft
Citalopram Celexa
Escitalopram Lexapro
Vilazodone* Viibryd
Serotonin norepinephrine
reuptake inhibitors
Venlafaxine Effexor, Effexor XR
Desvenlafaxine Pristiq
Duloxetine Cymbalta
Tricyclic antidepressants Clomipramine Anafranil
*Vilazodone was included because of the pharmacology of the drug, but no cases of
serotonin syndrome associated with Vilazodone have been reported.
Case Reportsas this finding is most strongly associated with serotonin
toxicity.U.S. FDA Safety Communication
During the past year, the U.S. FDA published drug
safety communications that detail serious reactions when
methylene blue is administered to patients taking psychiat-
ric medications. On July 26, 2011, a drug safety communi-
cation was published recommending that methylene blue
should generally not be given to patients taking serotoner-
gic drugs.18 Furthermore, in nonemergency situations
when methylene blue is contemplated and planned, the
FDA recommends the serotonergic psychiatric medication
be stopped at least 2 weeks in advance of methylene blue
treatment and not resumed until 24 hours after the last
dose of methylene blue. Specifically, fluoxetine, which
has a longer half-life, should be stopped 5 weeks in
advance.
The warning was updated in October 2011 as additional
cases were brought to the attention of the FDA Adverse
Event Reporting System.19 The FDA stated the cases of se-
rotonin syndromewith methylene bluewerewith a selective
serotonin reuptake inhibitor (SSRI), serotonin norepineph-
rine reuptake inhibitor, or clomipramine, a tricyclic antide-
pressant (Table 1). It is unknown whether the combination
of methylene blue and other psychiatric medications has
the same level of risk.CONCLUSIONS
Depression is quite common in patients awaiting organ
transplantation. Long-term illness, looming transplantation,
the stress of an LVAD and its multiple potential complica-
tions, and the unpredictability of receiving a transplant
even as a status 1A all contribute to the psychiatric burdenThe Journal of Thoracic and Carfor these individuals. A review of post-LVAD patients by
Shapiro and colleagues20 confirmed 83% required a psychi-
atric intervention and 20% had a major depressive episode.
Although this is an older study at a single institution, it is
representative of the LVAD population awaiting transplan-
tation. At the University of Virginia, we reviewed the last
36 months and found 18 of 47 patients who underwent
transplantation (38%) were on an SSRI at the time of
transplantation.
In an effort to balance the risks and benefits of antidepres-
sant therapies, we have come to realize it is not possible to
eliminate SSRIs from the management of depression in the
LVAD patient population. Weighing the risks of serotonin
syndrome, which only occurs in a small fraction of patients
and is treatable with benzodiazepines and supportive care,
vs the risk of untreated vasoplegia and potential end-
organ damage and graft loss, we have continued to include
methylene blue in the management of severe VS. As
such, our current practice is to dose methylene blue 1 to 2
mg/kg as a bolus over 20 to 30 minutes followed by 0.5
to 1 mg/kg per hour over 6 hours at the onset of refractory
hypotension or at the time of delivery of the terminal warm
cardioplegia dose immediately prior to unclamping and re-
perfusing the heart. For patients on an SSRI, it is our prac-
tice to exhaust more traditional inotropes, vasopressors, and
volume resuscitation for the initial management of VS, and
to reserve methylene blue for truly refractory hypotension.
Further research is needed to understand this issue more
completely. The total number of patients on the transplanta-
tion list who are taking antidepressants is unknown at this
time. We present this case as a means of generating discus-
sion and to caution the use of methylene blue in transplant
patients who are on antidepressant therapy.References
1. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and
management. Semin Thorac Cardiovasc Surg. 2010;22:140-4.
2. Gomes WJ, Carvalho AC, Palma JH, Goncalves I Jr, Buffolo E. Vasoplegic
syndrome: a new dilemma. J Thorac Cardiovasc Surg. 1994;107:942-3.
3. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascu-
lar resistance after cardiopulmonary bypass: incidence, etiology, and clinical
importance. J Card Surg. 2000;15:347-53.
4. Patarroyo M, Simbaqueba C, Shrestha K, Starling RC, Smedira N, Tang WH,
et al. Pre-operative risk factors and clinical outcomes associated with vasoplegia
in recipients of orthotopic heart transplantation in the contemporary era. J Heart
Lung Transplant. November 23, 2011 [Epub ahead of print].
5. Palmer RM. The discovery of nitric oxide in the vessel wall: a unifying concept in
the pathogenesis of sepsis. Arch Surg. 1993;128:396-401.
6. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J.
1993;14:22-6.
7. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD,
et al. Management of vasodilatory shock after cardiac surgery: identification
of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc
Surg. 1998;116:973-80.
8. Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose
methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg.
1999;118:195-6.
9. Pagni S, Austin EH. Use of intravenous methylene blue for the treatment of re-
fractory hypotension after cardiopulmonary bypass. J Thorac Cardiovasc Surg.
2000;119:1297-8.diovascular Surgery c Volume 144, Number 5 e115
Case Reports10. Andrade J, Batista M, Evora P, Tavares JR, Buffolo E, Ribeire EE, et al. Methy-
lene blue administration in the treatment of the vasoplegic syndrome after cardiac
surgery. Rev Bras Circ Cardiovasc. 1996;11:207-14.
11. Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B, et al.
Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after
cardiopulmonary bypass? J Thorac Cardiovasc Surg. 2003;125:1426-31.
12. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al.
Methylene blue reduces mortality and morbidity in vasoplegic patients after
cardiac surgery. Ann Thorac Surg. 2004;77:496-9.
13. Stanford SC, StanfordBJ,Gillman PK.Risk of severe serotonin toxicity following
co-administration of methylene blue and serotonin reuptake inhibitors: an update
on a case report of post-operative delirium. J Psychopharmacol. 2010;24:1433-8.
14. Gillman PK. CNS toxicity involving methylene blue: the exemplar for under-
standing and predicting drug interactions that precipitate serotonin toxicity.
J Psychopharmacol. 2011;25:429-36.
15. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-13.From the Department of Thoracic Surgery, Georges Pompidou European Hospital,
Paris-Descartes University, Paris, France.
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publication March 22, 2012; revisions received July 5, 2012; accepted
for publication Aug 1, 2012; available ahead of print Aug 23, 2012.
Address for reprints: Marc Riquet, PhD, MD, Department of Thoracic Surgery,
Georges Pompidou European Hospital, 20 rue Leblanc 75015, Paris, France
(E-mail: marc.riquet@egp.aphp.fr).
J Thorac Cardiovasc Surg 2012;144:e116-7
0022-5223/$36.00
Copyright  2012 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2012.08.001
e116 The Journal of Thoracic and Cardiovascular Sur16. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter sero-
tonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin
toxicity. Q J Med. 2003;96:635-42.
17. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:
1112-20.
18. Food andDrugAdministration. FDAdrug safety communication: serious CNS re-
actions possible when methylene blue is given to patients takeing certain psychi-
atric medications. 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/
ucm263190.htm. Accessed January 14, 2012.
19. Food and Drug Administration. FDA drug safety communication: updated infor-
mation about the drug interaction between methylene blue (methylthioninium
chloride) and serotonergic psychiatric medication. 2011. Available from: http://
www.fda.gov/Drugs/DrugSafety/ucm276119.htm. Accessed January 14, 2012.
20. Shapiro PA, Levin HR, Oz MC. Left ventricular assist devices: psychosocial bur-
den and implications for heart transplant programs. Gen Hosp Psychiatry. 1996;
18:30S-5S.The reliability of lung function tests in a quadriplegic patientPierre Emmanuel Noly, MD, Alex Arame, MD, Marc Riquet, PhD, MD, and
Franc¸oise Le Pimpec-Barthes, PhD, MD, Paris, FranceThere are few quadriplegic patients who require thoracic
surgery.1 Aweak capability to cough may lead to retention
of pulmonary secretions and consequently life-threatening
infectious complications,2 particularly during the postoper-
ative course. Surgery remains the only radical treatment of
endangering conditions, such as lung aspergilloma compli-
cated by hemoptysis.3 Lung resection usually requires a pre-
dicted postoperative forced expiratory volume in 1 second
(FEV1) exceeding 30%; otherwise, resection may be asso-
ciated with a high postoperative mortality.CLINICAL SUMMARY
A 35-year-old man was involved in a motor accident
(12 years previously) causing T8 paraplegia complicated
by phlebitis and pulmonary embolism. He underwent
T3-L3 arthrodesis 7 years later to correct post-traumatic
kyphoscoliosis that was complicated by C6 quadriplegia
(with partial left arm mobility) and several bacterial pneu-
monias resulting in destruction of the right upper lobe, fol-
lowed by aspergilloma formation and mild hemoptysis
occurring several times per day. Treatment with an oralantifungic drug was stopped because of liver complication
(cytolysis). Itraconazole proved to be ineffective. Asper-
gillous serology remained positive, and hemoptysis con-
tinued. Lobectomy was declined by 2 thoracic surgery
centers because of the patient’s low FEV1: 570 mL
(13% of the predicted value).
The patient was referred to the Georges Pompidou Euro-
pean Hospital. He had no dyspnea, and room air saturation
was 99% at rest. He was able to move himself using
a wheelchair, but he had swallowing problems and an in-
ability to cough. No abdominal muscle activity or accessory
respiratory muscle contraction was observed. After 2 weeks
in a pulmonary prehabilitation program, spirometry did not
improve. FEV1 was still 13%, vital capacity was 25%
(1350 mL), and diffusing capacity of the lung for carbon
monoxide was 37%. Arterial oxygen tension was 100 mm
Hg, and arterial carbon dioxide tension was 45 mm Hg.
However, except for an aspergilloma, the lung parenchyma
was disease-free on the computed tomography scan, and
lung perfusion was uniformly homogeneous in both lungs
on ventilation-perfusion scan. We suspected that the real re-
spiratory function was underestimated by spirometry and
not interpretable in this patient. C6 quadriplegia explained
the respiratory weakness with an FEV1 less than 20% of
predicted. A right upper lobectomy was performed by
video-assisted thoracoscopic surgery. A temporary prophy-
lactic tracheostomy was performed to manage postopera-
tive expectorating incapability problems and swallowing
difficulties. The postoperative course was uneventful. The
patient was weaned from mechanical ventilation within
24 hours, and the tracheostomy tube was removed on post-
operative day 9. Intense chest physiotherapy continuedgery c November 2012
